SCHEMBL5356429

SCHEMBL5356429

CC(C)(C)[Si](C)(C)Oc1ccc(C2CCC(NS(=O)(=O)c3ccccc3)CC2)c(O[Si](C)(C)C(C)(C)C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 7/20 0.42
HTR7 P34969 7/20 0.42
DRD2 P14416 5/20 0.41
BRD4 O60885 1/20 0.40
BRD2 P25440 1/20 0.40
BRD3 Q15059 1/20 0.40
ALDH1A1 P00352 3/20 0.40
HTR2A P28223 2/20 0.40
DRD3 P35462 2/20 0.40
KDM4E B2RXH2 2/20 0.40
HPGD P15428 2/20 0.40
HTT P42858 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
LMNA P02545 2/20 0.40
ADRA1D P25100 2/20 0.39
ADRA1A P35348 2/20 0.39
ADRA1B P35368 2/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
MCOLN2 Q8IZK6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5356423 1.00 HTR1A (0.42) HTR1AHTR7DRD2BRD4BRD2
SCHEMBL5363019 1.00 HTR1A (0.42) HTR1AHTR7DRD2BRD4BRD2
SCHEMBL5446988 0.91 POLB (0.42) DRD2HTR2ADRD3ADRA1DADRA1A
SCHEMBL5363070 0.91 ALDH1A1 (0.45) DRD2BRD4BRD2BRD3ALDH1A1
SCHEMBL5360944 0.91 POLB (0.40) DRD2ALDH1A1HTR2ADRD3KDM4E
SCHEMBL5359455 0.91 ALDH1A1 (0.45) DRD2BRD4BRD2BRD3ALDH1A1
SCHEMBL5446985 0.91 POLB (0.42) DRD2HTR2ADRD3ADRA1DADRA1A
SCHEMBL5359450 0.91 ALDH1A1 (0.45) DRD2BRD4BRD2BRD3ALDH1A1
SCHEMBL5360942 0.91 POLB (0.40) DRD2ALDH1A1HTR2ADRD3KDM4E
SCHEMBL5356019 0.90 KMT2A (0.43) DRD2BRD4BRD2BRD3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7282592-B2 Resorcinol derivatives WARNER-LAMBERT COMPANY (US) 2007-10-16 US disclosed
US-20070122367-A1 RESORCINOL DERIVATIVES PFIZER INC. (US) 2007-05-31 US disclosed
US-7173052-B2 Resorcinol derivatives PFIZER INC. (US) 2007-02-06 US disclosed
US-20050282899-A1 Resorcinol for lightening skin removing color BRADLEY STUART E 2005-12-22 US disclosed
US-6852747-B2 Resorcinol derivatives PFIZER INC. (US) 2005-02-08 US disclosed
US-20030180236-A1 Resorcinol derivatives PFIZER PRODUCTS, INC. 2003-09-25 US disclosed
US-6590105-B2 For skin lightening or depigmentation; works by inhibiting tyrosinase in humans; kits WARNER-LAMBERT COMPANY 2003-07-08 US disclosed
US-20020114770-A1 Resorcinol derivatives PFIZER INC. 2002-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070122367-A1 RESORCINOL DERIVATIVES LRAT, NQO1, ALDH1A2 HTR1A 3210/4885HTR7 4318/4885DRD2 426/4885
US-20030180236-A1 Resorcinol derivatives LRAT, NQO1, ALDH1A2 HTR1A 3210/4885HTR7 4318/4885DRD2 426/4885
US-20050282899-A1 Resorcinol for lightening skin removing color RBP4, NQO1, ALDH1A2 HTR1A 3659/4885HTR7 4226/4885DRD2 328/4885
US-20020114770-A1 Resorcinol derivatives LRAT, NQO1, ALDH1A2 HTR1A 3210/4885HTR7 4318/4885DRD2 426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.